KRAS and non-small cell lung carcinoma: Although palbociclib, another CDK4/6i, hasn’t shown relevant clinical activity in patients with pretreated NSCLC harboring cell cycle gene alterations (107), preclinical data suggest that the combination of palbociclib and MEKi has synergistic antitumoral and radiosensitizing effects on KRAS mutated NSCLC cell lines (108, 109); different clinical trials are evaluating this combination in the clinical setting (NCT03170206; NCT02022982).